Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Viewpoint - Aptorum Group Limited and DiamiR Biosciences Corp. are collaborating on a merger, with DiamiR set to become a wholly-owned subsidiary of Aptorum, pending shareholder approval and customary closing conditions [3]. Company Overview Aptorum Group - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [4]. DiamiR Biosciences - DiamiR is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology protected by over 50 patents worldwide [5]. Merger Details - The merger between Aptorum and DiamiR was announced on July 16, 2025, and is expected to close in the fourth quarter of 2025, subject to stockholder approval [3]. - DiamiR's CEO, Alidad Mireskandari, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [2].